Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/21374
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | PERUALILA, Nolen Joy | - |
dc.contributor.author | KASIM, Adetayo | - |
dc.contributor.author | TALLOEN, Willem | - |
dc.contributor.author | Goehlmann, Hinrich | - |
dc.contributor.author | SHKEDY, Ziv | - |
dc.date.accessioned | 2016-06-01T10:37:02Z | - |
dc.date.available | 2016-06-01T10:37:02Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | JSM Proceedings, Biopharmaceutical Session, p. 3021-3030 | - |
dc.identifier.uri | http://hdl.handle.net/1942/21374 | - |
dc.description.abstract | Quantitative Structure Transcriptional Activity Relationship (QSTAR) involves relating the three data sources in early drug discovery namely (1) chemical structure (fingerprint features), (2) bioactivity (bio-assay read-outs) data for targets of interest, and (3) transcriptomic (gene expression) data of a set of compounds. In this paper, a gene-specific and fingerprint feature-specific joint model is presented as a tool to model the association between gene expression and biological activity taking into account the chemical structure of the compounds. The model allows to detect genes that are associated to the bio-assay read-out for which some of the associations are mainly induced by certain fingerprint feature(s) of compounds. The joint model is applied to two oncology projects. Results show that a number of compounds’ fingerprint features have differential effects on both bio-assay read-outs and a set of correlated genes. | - |
dc.language.iso | en | - |
dc.subject.other | bioactivity; chemical structures; joint model; QSTAR; transcriptomic | - |
dc.title | Development of genetic biomarkers in drug discovery and early drug development experiments | - |
dc.type | Proceedings Paper | - |
local.bibliographicCitation.conferencedate | August 2-7,2014 | - |
local.bibliographicCitation.conferencename | Joint Statistical Meetings | - |
local.bibliographicCitation.conferenceplace | Boston, Massachusetts, USA | - |
dc.identifier.epage | 3030 | - |
dc.identifier.spage | 3021 | - |
local.bibliographicCitation.jcat | C2 | - |
local.publisher.place | Alexandria | - |
local.type.refereed | Non-Refereed | - |
local.type.specified | Proceedings Paper | - |
local.bibliographicCitation.btitle | JSM Proceedings, Biopharmaceutical Session | - |
item.fulltext | With Fulltext | - |
item.fullcitation | PERUALILA, Nolen Joy; KASIM, Adetayo; TALLOEN, Willem; Goehlmann, Hinrich & SHKEDY, Ziv (2014) Development of genetic biomarkers in drug discovery and early drug development experiments. In: JSM Proceedings, Biopharmaceutical Session, p. 3021-3030. | - |
item.accessRights | Restricted Access | - |
item.contributor | PERUALILA, Nolen Joy | - |
item.contributor | KASIM, Adetayo | - |
item.contributor | TALLOEN, Willem | - |
item.contributor | Goehlmann, Hinrich | - |
item.contributor | SHKEDY, Ziv | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
JSM proceeding.pdf Restricted Access | 467.6 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.